These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 20332565)

  • 1. In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery.
    Wang Y; Zhang D; Liu Z; Liu G; Duan C; Jia L; Feng F; Zhang X; Shi Y; Zhang Q
    Nanotechnology; 2010 Apr; 21(15):155104. PubMed ID: 20332565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs.
    Yan-yu X; Yun-mei S; Zhi-peng C; Qi-neng P
    Int J Pharm; 2006 Aug; 319(1-2):162-8. PubMed ID: 16687221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo absorption comparison of nanotechnology-based silybin tablets with its water-soluble derivative.
    Xu D; Ni R; Sun W; Li LC; Mao S
    Drug Dev Ind Pharm; 2015 Apr; 41(4):552-9. PubMed ID: 24495272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.
    Lai F; Sinico C; Ennas G; Marongiu F; Marongiu G; Fadda AM
    Int J Pharm; 2009 May; 373(1-2):124-32. PubMed ID: 19429297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization.
    Xu Y; Liu X; Lian R; Zheng S; Yin Z; Lu Y; Wu W
    Int J Pharm; 2012 Nov; 438(1-2):287-95. PubMed ID: 22989976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats.
    Yanyu X; Yunmei S; Zhipeng C; Qineng P
    Int J Pharm; 2006 Jan; 307(1):77-82. PubMed ID: 16300915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability.
    Xia D; Quan P; Piao H; Piao H; Sun S; Yin Y; Cui F
    Eur J Pharm Sci; 2010 Jul; 40(4):325-34. PubMed ID: 20417274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies.
    Jia L; Zhang D; Li Z; Duan C; Wang Y; Feng F; Wang F; Liu Y; Zhang Q
    Colloids Surf B Biointerfaces; 2010 Oct; 80(2):213-8. PubMed ID: 20621458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo evaluation of silybin nanosuspensions targeting liver.
    Wang Y; Wang L; Liu Z; Zhang D; Zhang Q
    J Biomed Nanotechnol; 2012 Oct; 8(5):760-9. PubMed ID: 22888746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation, characterization and in vivo evaluation of amorphous tacrolimus nanosuspensions produced using CO2-assisted in situ nanoamorphization method.
    Wang Y; Han X; Wang J; Wang Y
    Int J Pharm; 2016 May; 505(1-2):35-41. PubMed ID: 27034003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
    Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
    Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: in vitro release kinetics and in vitro/in vivo correlations in beagle dogs.
    Cao X; Deng W; Fu M; Zhu Y; Liu H; Wang L; Zeng J; Wei Y; Xu X; Yu J
    Eur J Pharm Sci; 2013 Jan; 48(1-2):64-71. PubMed ID: 23123331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and comparison of intramuscularly long-acting paliperidone palmitate nanosuspensions with different particle size.
    Leng D; Chen H; Li G; Guo M; Zhu Z; Xu L; Wang Y
    Int J Pharm; 2014 Sep; 472(1-2):380-5. PubMed ID: 24882037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development.
    Sigfridsson K; Lundqvist AJ; Strimfors M
    Drug Dev Ind Pharm; 2009 Dec; 35(12):1479-86. PubMed ID: 19929207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation.
    Freag MS; Elnaggar YS; Abdallah OY
    Int J Pharm; 2013 Sep; 454(1):462-71. PubMed ID: 23830765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
    Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
    Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.
    Gao L; Zhang D; Chen M; Duan C; Dai W; Jia L; Zhao W
    Int J Pharm; 2008 May; 355(1-2):321-7. PubMed ID: 18242896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new drug nanocrystal self-stabilized Pickering emulsion for oral delivery of silybin.
    Yi T; Liu C; Zhang J; Wang F; Wang J; Zhang J
    Eur J Pharm Sci; 2017 Jan; 96():420-427. PubMed ID: 27575878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation and Evaluation of Naringenin Nanosuspensions for Bioavailability Enhancement.
    Gera S; Talluri S; Rangaraj N; Sampathi S
    AAPS PharmSciTech; 2017 Nov; 18(8):3151-3162. PubMed ID: 28534300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oil based nanocarrier for improved oral delivery of silymarin: In vitro and in vivo studies.
    Parveen R; Baboota S; Ali J; Ahuja A; Vasudev SS; Ahmad S
    Int J Pharm; 2011 Jul; 413(1-2):245-53. PubMed ID: 21549187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.